CARsgen Therapeutics Holdings Limited, a prominent player in the field of CAR T-cell therapies, has announced the successful completion of patient enrollment for its pivotal Phase II clinical trial of Satri-cel (satricabtagene autoleucel). This advanced autologous CAR T-cell product candidate targets Claudin18.2 and aims to treat patients with advanced gastric and gastroesophageal junction cancers (GC/GEJ) […]
Vimgreen Pharmaceuticals has marked a significant milestone with the completion of participant enrollment in its Phase 2 clinical trial for VG081821AC, a cutting-edge treatment for Parkinson’s disease. This trial, involving 150 participants, aims to explore the efficacy and safety of VG081821AC, an adenosine A2A receptor (A2AR) antagonist and inverse agonist, specifically for individuals in the […]
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy in treating non-squamous non-small cell lung cancer. The study did not meet its primary endpoints of progression-free survival (PFS) and overall survival (OS), signaling a setback in […]
Dynavax Technologies Corporation, a renowned player in the biopharmaceutical sector, has made headlines with the initiation of a Phase 1/2 clinical trial for its innovative shingles vaccine candidate, Z-1018. This trial marks a significant step in the development of a vaccine aimed at preventing shingles, a painful condition caused by the reactivation of the varicella-zoster […]
Indivior PLC (LSE/Nasdaq: INDV) has announced the commencement of a Phase 2 clinical trial involving INDV-2000, a non-opioid treatment, marking a significant advancement in the battle against Opioid Use Disorder (OUD). This double-blind, placebo-controlled, randomized study is designed to assess the safety and efficacy of INDV-2000 over a three-month period in individuals with moderate to […]
Oxford BioDynamics Plc (AIM: OBD), a pioneering biotechnology company, has announced its participation in a significant clinical trial led by the National Cancer Institute (NCI) of the National Institutes of Health, Bethesda, Maryland. The trial will utilize the EpiSwitch Prostate Screening (PSE) test, developed by Oxford BioDynamics, in correlative studies aimed at improving the monitoring […]
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that the first patients with diabetic retinopathy have been treated in the Phase 3 GLOW2 study of tarcocimab tedromer. This milestone marks a significant advancement in the ongoing research and development efforts aimed at combating retinal diseases. Key […]
In a significant advancement for the treatment of Duchenne muscular dystrophy (DMD), Italfarmaco S.p.A. has announced the U.S. Food and Drug Administration (FDA) approval of Duvyzat (givinostat), a novel histone deacetylase (HDAC) inhibitor, for patients aged 6 and older. This approval signifies a major milestone in the management of DMD, a rare and progressive neuromuscular […]
Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase 2 clinical trial. The trial aims to evaluate its ready-to-use, room temperature-stable glucagon in patients with Type 1 diabetes who suffer from exercise-induced hypoglycemia (EIH). This is a critical step for the company as it looks to […]
Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for its investigational drug verdiperstat for treating multiple system atrophy (MSA). This rare and debilitating neurodegenerative disease has long been a target for pharmaceutical companies seeking breakthroughs in treatment, and verdiperstat’s designation underscores its potential as a game-changer […]
